| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
14,410,000 |
| Market
Cap: |
4.80(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3333 - $0.3333 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
85,262 |
| Total Buy Value |
$0 |
$0 |
$0 |
$197,404 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bendekgey E Lee |
CFO and Treasurer |
• – – |
2008-05-30 |
5 |
A |
$13.09 |
$2,801 |
D/D |
214 |
1,502 |
|
- |
|
| Love Ted W |
C.E.O |
• • – |
2008-03-24 |
4 |
B |
$0.67 |
$19,479 |
D/D |
29,000 |
57,289 |
2.81 |
- |
|
| Love Ted W |
Director |
– • – |
2008-02-29 |
5 |
A |
$28.39 |
$16,353 |
D/D |
576 |
3,580 |
|
- |
|
| Bendekgey E Lee |
CFO and Treasurer |
• – – |
2008-02-29 |
5 |
A |
$28.39 |
$2,811 |
D/D |
99 |
1,502 |
|
- |
|
| Bendekgey E Lee |
Sr. VP CFO and General Counsel |
• – – |
2007-11-30 |
4 |
A |
$1.48 |
$2,857 |
D/D |
1,932 |
6,511 |
|
- |
|
| Bendekgey E Lee |
Sr. VP CFO and General Counsel |
• – – |
2007-08-31 |
4 |
A |
$1.85 |
$2,678 |
D/D |
1,445 |
4,579 |
|
- |
|
| Levy Michael D |
Executive Vice President |
• – – |
2007-08-31 |
4 |
A |
$1.85 |
$6,680 |
D/D |
3,605 |
20,821 |
|
- |
|
| Love Ted W |
C.E.O. |
• • – |
2007-08-31 |
4 |
A |
$1.85 |
$2,961 |
D/D |
1,598 |
28,289 |
|
- |
|
| Bendekgey E Lee |
Sr. VP CFO and General Counsel |
• – – |
2007-05-31 |
4 |
A |
$2.90 |
$2,678 |
D/D |
924 |
3,134 |
|
- |
|
| Levy Michael D |
Executive Vice President |
• – – |
2007-05-31 |
4 |
A |
$2.90 |
$10,249 |
D/D |
3,536 |
17,216 |
|
- |
|
| Love Ted W |
C.E.O. |
• • – |
2007-05-31 |
4 |
A |
$2.90 |
$16,374 |
D/D |
5,649 |
26,691 |
|
- |
|
| Bendekgey E Lee |
Sr. VP CFO and General Counsel |
• – – |
2007-02-28 |
4 |
A |
$2.79 |
$2,682 |
D/D |
962 |
2,210 |
|
- |
|
| Bendekgey E Lee |
Sr VP & General Counsel |
• – – |
2006-11-30 |
4 |
A |
$16.32 |
$2,676 |
D/D |
164 |
1,248 |
|
- |
|
| Levy Michael D |
Sr. VP Research & Development |
• – – |
2006-11-30 |
4 |
A |
$16.32 |
$685 |
D/D |
42 |
4,680 |
|
- |
|
| Wolff Henry Ward |
Sr. VP Finance and CFO |
• – – |
2006-11-30 |
4 |
A |
$16.32 |
$3,737 |
D/D |
229 |
229 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-11-10 |
4 |
AS |
$18.17 |
$227,136 |
D/D |
(12,500) |
0 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-11-10 |
4 |
OE |
$6.50 |
$81,250 |
D/D |
12,500 |
12,500 |
|
- |
|
| Perry Mark L |
Director |
– • – |
2006-09-28 |
4 |
OE |
$6.50 |
$596,989 |
D/D |
65,833 |
65,833 |
|
- |
|
| Bendekgey E Lee |
Sr VP & General Counsel |
• – – |
2006-08-31 |
4 |
A |
$14.20 |
$2,641 |
D/D |
186 |
1,084 |
|
- |
|
| Levy Michael D |
Sr. VP Research & Development |
• – – |
2006-08-31 |
4 |
A |
$14.20 |
$9,912 |
D/D |
698 |
4,638 |
|
- |
|
| Love Ted W |
C.E.O. |
• • – |
2006-08-31 |
4 |
A |
$14.20 |
$4,146 |
D/D |
292 |
21,042 |
|
- |
|
| Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-30 |
4 |
S |
$20.70 |
$289,800 |
D/D |
(14,000) |
2,633 |
|
- |
|
| Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-30 |
4 |
OE |
$2.60 |
$36,330 |
D/D |
14,000 |
16,633 |
|
- |
|
| Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-29 |
4 |
S |
$20.65 |
$141,060 |
D/D |
(6,831) |
2,633 |
|
- |
|
| Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-29 |
4 |
OE |
$9.17 |
$62,606 |
D/D |
6,831 |
9,464 |
|
- |
|
240 Records found
|
|
Page 8 of 10 |
|
|
